[go: up one dir, main page]

WO2005097779A1 - Derives de diarylamine utilises comme bloquants des canaux calciques - Google Patents

Derives de diarylamine utilises comme bloquants des canaux calciques Download PDF

Info

Publication number
WO2005097779A1
WO2005097779A1 PCT/CA2005/000544 CA2005000544W WO2005097779A1 WO 2005097779 A1 WO2005097779 A1 WO 2005097779A1 CA 2005000544 W CA2005000544 W CA 2005000544W WO 2005097779 A1 WO2005097779 A1 WO 2005097779A1
Authority
WO
WIPO (PCT)
Prior art keywords
phenyl
piperazin
methyl
diphenyl
acetamide
Prior art date
Application number
PCT/CA2005/000544
Other languages
English (en)
Inventor
Hassan Pajouhesh
Hossein Pajouhesh
Yanbing Ding
Terrance P. Snutch
Original Assignee
Neuromed Pharmaceuticals Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/821,584 external-priority patent/US20040259866A1/en
Priority claimed from US10/928,564 external-priority patent/US20050227999A1/en
Application filed by Neuromed Pharmaceuticals Ltd. filed Critical Neuromed Pharmaceuticals Ltd.
Priority to CA002562371A priority Critical patent/CA2562371A1/fr
Priority to MXPA06011629A priority patent/MXPA06011629A/es
Priority to AU2005231872A priority patent/AU2005231872A1/en
Priority to JP2007506628A priority patent/JP2007532492A/ja
Priority to BRPI0509715-0A priority patent/BRPI0509715A/pt
Priority to EP05734348A priority patent/EP1745042A4/fr
Publication of WO2005097779A1 publication Critical patent/WO2005097779A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/06—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members
    • C07D241/08—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/145—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/15—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/58—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Definitions

  • the invention relates to compounds useful in treating conditions associated with calcium channel function. More specifically, the invention concerns compounds containing substituted or unsubstituted diarylamine derivatives of 6-membered heterocyclic moieties that are useful in treatment of conditions such as stroke and pain.
  • Calcium channels mediate a variety of normal physiological functions, and are also implicated in a number of human disorders.
  • Examples of calcium-mediated human disorders include but are not limited to congenital migraine, cerebellar ataxia, angina, epilepsy, hypertension, ischemia, and some arrhythmias.
  • the clinical treatment of some of these disorders has been aided by the development of therapeutic calcium channel antagonists (e.g., dihydropyridines, phenylalkylamines, and benzothiazepines all target L-type calcium channels) (Janis and Triggle, 1991).
  • therapeutic calcium channel antagonists e.g., dihydropyridines, phenylalkylamines, and benzothiazepines all target L-type calcium channels
  • T-type (or low voltage-activated) channels describe a broad class of molecules that transiently activate at negative potentials and are highly sensitive to changes in resting potential.
  • L-, N- and P/Q-type channels activate at more positive potentials (high voltage-activated) and display diverse kinetics and voltage-dependent properties (Catterall, 2000; Huguenard 1996).
  • L-type channels can be distinguished by their sensitivity to several classes of small organic molecules used therapeutically, including dihydropyridines (DHPs), phenylalkylamines and benzothiazepines.
  • DHPs dihydropyridines
  • phenylalkylamines phenylalkylamines
  • benzothiazepines are high affinity targets for certain peptide toxins produced by venous spiders and marine snails: N-type channels are blocked by the ⁇ -conopeptides ⁇ -conotoxin GVIA ( ⁇ -CTx-GVIA) isolated from Conus geographus and ⁇ -conotoxin MVIIA ( ⁇ -CTx-MVIIA) isolated from Conus magus, while P/Q-type channels are resistant to ⁇ -CTx-MVIIA but are sensitive to the funnel web spider peptide, ⁇ -agatoxin INA ( ⁇ -Aga-IVA).
  • R-type calcium channels are sensitive to block by the tarantula toxin, S ⁇ X-482.
  • Neuronal high voltage-activated calcium channels are composed of a large (>200 kDa) pore-forming ⁇ i subunit that is the target of identified pharmacological agents, a cytoplasmically localized ⁇ 50-70 kDa ⁇ subunit that tightly binds the ⁇ i subunit and modulates channel biophysical properties, and an ⁇ 170 kDa ⁇ 2 ⁇ subunit (reviewed by Stea, et al, 1994; Catterall, 2000).
  • nine different oti subunit genes expressed in the nervous system have been identified and shown to encode all of the major classes of native calcium currents (Table 1).
  • mice null for the a N-type calcium channel gene have been reported by several independent groups (Ino, et al, 2001; Kim, et ah, 2001; Saegusa, et ah, 2001 ; Hatakeyama, et ah, 2001).
  • the C IB N-type null mice were viable, fertile and showed normal motor coordination.
  • peripheral body temperature, blood pressure and heart rate in the N-type gene knock-out mice were all normal (Saegusa, et al, 2001).
  • the baroreflex mediated by the sympathetic nervous system was reduced after bilateral carotid occlusion (Ino, et al, 2001).
  • mice were examined for other behavioral changes and were found to be normal except for exhibiting significantly lower anxiety-related behaviors (Saegusa, et al, 2001), suggesting the N-type channel may be a potential target for mood disorders as well as pain.
  • mice lacking functional N-type channels exhibit marked decreases in the chronic and inflammatory pain responses.
  • mice lacking N-type channels generally showed normal acute nociceptive responses.
  • Two examples of either FDA-approved or investigational drug that act on N-type channel are gabapentin and ziconotide.
  • Gabapentiri, l-(aminomethyl) cyclohexaneacetic acid is an anticonvulsant originally found to be active in a number of animal seizure models (Taylor, et al, 1998).
  • gabapentin is also successful at preventing hyperalgesia in a number of different animal pain models, including chronic constriction injury (CCI), heat hyperalgesia, inflammation, diabetic neuropathy, static and dynamic mechanoallodynia associated with postoperative pain (Taylor, et al, 1998; Cesena & Calcutt, 1999; Field, et al, 1999; Cheng, J-K., et al, 2000; Nicholson, 2000). [0011] While its mechanism of action is incompletely understood, current evidence suggests that gabapentin does not directly interact with GA 3A receptors in many neuronal systems, but rather modulates the activity of high threshold calcium channels.
  • Gabapentin has been shown to bind to the calcium channel ⁇ 2 ⁇ ancillary subunit, although it remains to be determined whether this interaction accounts for its therapeutic effects in neuropathic pain. [0012] In humans, gabapentin exhibits clinically effective anti-hyperalgesic activity against a wide ranging of neuropathic pain conditions. Numerous open label case studies and three large double blind trials suggest gabapentin might be useful in the treatment of pain.
  • Ziconotide (Prialt ® ; SNX-111) is a synthetic analgesic derived from the cone snail peptide Conus magus MVIIA that has been shown to reversibly block N-type calcium channels.
  • the selective block of N-type channels via intrathecal administration of Ziconotide significantly depresses the formalin phase 2 response, thermal hyperalgesia, mechanical allodynia and post-surgical pain (Malmberg and Yaksh, 1994; Bowersox, et al, 1996; Sluka, 1998; Wang, et al, 1998).
  • Ziconotide has been evaluated in a number of clinical trials via intrathecal administration for the treatment of a variety of conditions including post-herpetic neuralgia, phantom limb syndrome, HIN-related neuropathic pain and intractable cancer pain (reviewed in Mathur, 2000).
  • phase II and III clinical trials with patients unresponsive to intrathecal opiates Ziconotide has significantly reduced pain scores and in a number of specific instances resulted in relief after many years of continuous pain.
  • Ziconotide is also being examined for the management of severe post-operative pain as well as for brain damage following stroke and severe head trauma (Heading, 1999).
  • T-type channels are highly expressed in tissues of the cardiovascular system. Mibefradil, a calcium channel blocker 10-30-fold selective for T-type over L-type channels, was approved for use in hypertension and angina. It was withdrawn from the market shortly after launch due to interactions with other drugs (Heady, et al, 2001). [0017] Growing evidence suggests T-type calcium channels may also be involved in pain.
  • A An essential component of these molecules is represented by A, which must be an antioxidant; the piperazine or piperidine itself is said to be important.
  • the exemplified compounds contain a benzhydril substituent, based on known calcium channel blockers (see below).
  • U.S. Pat. No. 5,703,071 discloses compounds said to be useful in treating ischemic diseases.
  • a mandatory portion of the molecule is a tropolone residue, with substituents such as piperazine derivatives, including their benzhydril derivatives.
  • U.S. Pat. No. 5,428,038 discloses compounds indicated to exhibit a neural protective and antiallergic effect. These compounds are coumarin derivatives which may include derivatives of piperazine and other six-membered heterocycles.
  • a permitted substituent on the heterocycle is diphenylhydroxymethyl.
  • approaches in the art for various indications which may involve calcium channel blocking activity have employed compounds which incidentally contain piperidine or piperazine moieties substituted with benzhydril but mandate additional substituents to maintain functionality.
  • Certain compounds containing both benzhydril moieties and piperidine or piperazine are known to be calcium channel antagonists and neuroleptic drugs.
  • Gould, R. I, et al, Proc Natl Acad Sci USA (1983) 80:5122-5125 describes antischizophrenic neuroleptic drugs such as lidoflazine, fluspirilene, pimozide, clopimozide, and penfluridol.
  • the invention relates to compounds useful in treating conditions such as stroke, anxiety, overactive bladder, inflammatory bowel disease, irritable bowel syndrome, interstitial colitis, head trauma, migraine, chronic, neuropathic and acute pain, drug and alcohol addiction, neurodegenerative disorders, psychoses, sleep disorders, depression, epilepsy, diabetes, cancer, male contraception, hypertension, pulmonary hypertension, cardiac arrhythmias, congestive heart failure, angina pectoris and other indications associated with calcium metabolism, including synaptic calcium channel-mediated functions.
  • the compounds of the invention are diarylamino derivatives of piperazine or amino piperidine with substituents that enhance the calcium channel blocking activity of the compounds.
  • the invention is directed to compounds of the fonnula
  • each of A and B is independently a 6-membered aromatic or nonaromatic, carbocyclic or heterocyclic moiety or is an aminoalkyl and wherein one and only one of A. and B may be H or alkyl (1-8C) or wherein A and B together form an optionally substituted 6-membered aromatic or nonaromatic, carbocyclic or heterocyclic moiety;
  • RMs H or alkyUl- ⁇ C
  • Z is N or CHNR 2 wherein R 2 is H or alkyl (1-8C);
  • the invention is also directed to methods to modulate calcium channel activity, preferably N-type and T-type channel activity, using the compounds of formula (1) and thus to treat certain undesirable physiological conditions; these conditions are associated with calcium channel activity.
  • the invention is directed to pharmaceutical compositions containing these compounds, and to the use of these compounds for the preparation of medicaments for the treatment of conditions requiring modulation of calcium channel activity, including stroke, anxiety, overactive bladder, inflammatory bowel disease, irritable bowel syndrome, interstitial colitis, head trauma, migraine, chronic, neuropathic and acute pain, drug and alcohol addiction, neurodegenerative disorders, psychoses, sleep disorders, depression, epilepsy, diabetes, cancer, male contraception, hypertension, pulmonary hypertension, cardiac arrhythmias, congestive heart failure and angina pectoris.
  • the compounds of formula (1) useful in the methods of the invention exert their desirable effects through their ability to modulate the activity of N-type and/or T-type calcium channels. This makes them useful for treatment of certain conditions.
  • Such conditions where antagonist activity is desired are stroke, anxiety, epilepsy, head trauma, migraine, inflammatory bowel disease, overactive " bladder in ⁇ table bowel syndrome, interstitial colitis and chronic, neuropathic and acute pain.
  • Calcium flux is also implicated in other neurological disorders such as schizophrenia;, anxiety, depression, other psychoses, neural degenerative disorders and drug and alcohol addiction and withdrawal.
  • Chronic pain can include cancer pain, inflammatory pain conditions related to osteoarthritis, rheumatoid arthritis and fibromyalgia, and neuropathic pain.
  • Neuropathic pain includes but is not limited to conditions such as diabetic peripheral neuropathy, post-herpetic neuralgia, trigeminal neuralgia, cancer pain and AIDS related neuropathy.
  • Acute pain conditions can include nociceptive pain and post-operative pain.
  • Anxiety includes but is not limited to the following conditions: generalized anxiety disorder, social anxiety disorder, panic disorder, obsessive-compulsive disorder, and post-traumatic stress syndrome.
  • Neurodegenerative disorders include Parkinson's disease, Alzheimer's disease, multiple sclerosis, neuropathies, Huntington's disease and amyotrophic lateral sclerosis (ALS).
  • ALS amyotrophic lateral sclerosis
  • Ttius As described below, they are screened for their ability to interact with N-type and/or T-type channels as an initial indication of desirable function. It is desirable that the compounds exhibit IC 50 values of ⁇ 1 ⁇ M.
  • the IC 5 o is the concentration which inhibits 50*% of the calcium, barium or other permeant divalent cation flux at a particular applied potential.
  • open channel blockage The first, designated “open channel blockage,” is conveniently demonstrated when displayed calcium channels are maintained at an artificially negative restin-g potential of about -100 mV (as distinguished from the typical endogenous resting maintained potential of about -70 mV).
  • closed channel blocking inhibitors diminish the current exhibited at the peak flow and can also accelerate the rate of current decay.
  • This type of inhibition is distinguished from a second type of block, referred to herein as "inactivation inhibition.”
  • inactivation inhibition When maintained at less negative; resting potentials, such as the physiologically important potential of -70 mV, a certain percentage of the channels may undergo conformational change, rendering them incapable of being activated — i.e., opened — by the abrupt depolarization. Thus, the peak current due to calcium ion flow will be diminished not because the open channel is blocked, but because some of the channels are unavailable for opening (inactivated).
  • “Inactivation” type inhibitors increase the percentage of receptors that are in an inactivated state.
  • a third type of inhibition is designated "resting channel block”.
  • Resting channel block is the inhibition of the channel that occurs in the absence of mesmbrane depolarization, that would normally lead to opening or inactivation. For example, resting channel blockers would diminish the peak current amplitude during the very first depolarization after drug application without additional inhibition during the depolarization. [0033] In order to be maximally useful in treatment, it is also helpful to assess the side reactions which might occur. Thus, in addition to being able to modmlate a particular calcium channel, it is desirable that the compound has very low activity with respect to the HERG K + channel which is expressed in the heart. Compounds that block this channel with high potency may cause reactions which are fatal.
  • the HERG K + channel is not inhibited.
  • the compound will be evaluated for calcium ion channel type specificity by comparing its activity among the various types of calcium channels, and specificity for one particular channel type is preferced. The compounds which progress through these tests successfully are then examined in animal models as actual drug candidates.
  • the compounds of the invention modulate the activity of calcium channels; in general, said modulation is the inhibition of the ability of the channel to transport calcium.
  • alkyl straight-chain, branched-chain and cyclic monovalent substituents, containing only C and H when they are unsubstituted or unless otherwise noted. Examples include methyl, ethyl, isobutyl, cyclohexyl, cyclopentylethyl, 2-propenyl, 3-butynyl, and the like.
  • alkyl, alkenyl and alkynyl substituents contain 1-lOC or 1-8C (alkyl) or 2-10C or 2-8C (alkenyl or alkynyl).
  • heteroalkyl, heteroalkenyl and heteroalkynyl are similarly defined but may contain one or more O, S or N heteroatoms or combinations thereof witbtin the backbone residue. These are "heteroforms" of the referent carbonaceous moiety.
  • the cyclic forms of alkyl, heteroalkyl, etc., including unsatuirated forms, are included within the definition as indicated above. This may also be explicitly stated as cycloalkyl or cycloheteroalkyl.
  • cycloalkyl might include cyclopentyl, cyclohexyl, cyclobutyl and the like; cycloalkenyl would include cyclohexenyl, cyclohexadienyl, cyclopentenyl, cyclopentadienyl, and so forth.
  • the heteroforms of these include substituents which comprise morpholine, piperazine, piperidine, thiazolidine, pyrroli ine, and the like. It is noted that in some embodiments, the substituents A and B, in combination with the carbon to which they are bound, form a 6-membered ring which includes piperazine, piperidine, morpholine, benzene, pyridine, and the like.
  • acyl encompasses the definitions of alkyl, alkenyl, alkynyl, each of which is coupled to an additional residue through a carbonyl group. ETeteroacyl includes the related heteroforms.
  • "Aromatic” moiety or “aryl” moiety refers to a monocyclic ox fused bicyclic moiety such as phenyl or naphthyl; “heteroaromatic” also refers to monocyclic or fused bicyclic ring systems containing one or more heteroatoms selected from O, S and N. The inclusion of a heteroatom permits inclusion of 5-membered rings to be considered aromatic as well as 6-membered rings.
  • aromatic/heteroaromatic systems include pyxidyl, pyrimidyl, indolyl, benzimidazolyl, benzotriazolyl, isoquinolyl, quinolyl, benzothiazolyl _ benzofuranyl, thienyl, furyl, pyrrolyl, thiazolyl, oxazolyl, imidazolyl and the like. Because tautomers are theoretically possible, phthalimido is also considered aromatic. Any monocyclic or fused ring bicyclic system which has the characteristics of aromaticity in terms of electron distribution throughout the ring system is included in this definition. Typically, the ring systems contain 5-12 ring member atoms.
  • arylalkyl and “heteroarylalkyl” refer to aromatic and heteroaronxatic systems which are coupled to another residue through a carbon chain, including substituted or unsubstituted, saturated or unsaturated, carbon chains, typically of 1-8C, or the hetero forms thereof. These carbon chains may also include a carbonyl group, thus making them able to provide substituents as an acyl or heteroacyl moiety.
  • any alkyl, alkenyl, alkynyl, acyl, or aryl (including the heterofornxs) group contained in a substituent may itself optionally be substituted by additional substituents.
  • substituents are similar to those recited with regard to the primary substituents themselves.
  • ttiis alkyl may optionally be substituted by the remaining substituents listed as substituents where this makes chemical sense, and where this does not undermine the size limit of alkyl er se; e.g., alkyl substituted by alkyl or by alkenyl would simply extend the upper limit of carbon atoms for these embodiments.
  • alkyl substituted by aryl, amino, alkoxy, and the like would be included.
  • Ar is preferably optionally substituted phenyl, 2-, 3- or 4-pyridyl, indolyl, 2- or 4-pyrimidyl, pyridazinyl, benzotriazolyl or benzimidazolyl. More preferably Ar is phenyl, pyridyl, or pyrimidyl. Most preferably Ar is phenyl.
  • Eact ⁇ of these embodiments may optionally be substituted with one or more groups defined above, such as alkyl, alkenyl, alkynyl, aryl, O-aryl, O-alkylaryl, O-aroyl, NR-aryl, N-alkylaryl, NR-aroyl, halo, OR, NR 2 , SR, -OOCR, -NROCR, RCO, -COOR, -CONR 2 , and/or SO 2 NR 2 , wherein each R is independently H or alkyl (1-8C), alkenyl (2-8C), alkynyl (2-8C), aryl or alkylaryl, and or by -CN, -CF 3 , and/or NO 2 .
  • groups defined above such as alkyl, alkenyl, alkynyl, aryl, O-aryl, O-alkylaryl, O-aroyl, NR-aryl, N-alkylaryl, NR-aroyl
  • Alkyl, alkenyl, alkynyl, cyclic and aryl portions of these may be further substituted by similar substituents.
  • substituents on Ar are alkyl, CF 3 , CHF 2 , OR, SR, NR 2 , where R is as above-defined, and halo.
  • Preferred embodiments of R 1 are methyl and H.
  • the compounds of the invention may have ionizable groups so as to be capable of preparation as pharmaceutically acceptable salts.
  • salts may be acid addition salts involving inorganic or organic acids or the salts may, in the case of acidic forms of the compounds of the invention be prepared from inorganic or organic bases.
  • Suitable pharmaceutically acceptable acids and bases are well-known in the art, such as hydrochloric, sulphuric, citric, acidic, or tartaric acids and potassium hydroxide, sodium hydroxide, ammonium hydroxide, caffeine, various amines, and the like. Methods for preparation of the appropriate salts are well-established in the art.
  • the compounds of the invention contain one or more chiral centers.
  • the invention includes the isolated stereoisomeric forms as well as mixtures of stereoisomers in varying degrees of chiral purity.
  • the compounds of the invention may be coupled through conjugation to substances designed to alter the pharmacokinetics, for targeting, or for other reasons.
  • the invention further includes conjugates of these compounds.
  • polyethylene glycol is often coupled to substances to enhance half-life; the compounds may be coupled to liposomes covalently or noncovalently or to other particulate carriers. They may also be coupled to targeting agents such as antibodies or peptidomimetics, often through linker moieties.
  • the invention is also directed to the compounds of fonnula (1) when modified so as to be included in a conjugate of this type.
  • the compounds of the invention may be synthesized using conventional methods.
  • the piperidine analog can be substituted and reaction of the nitrogen of CHNH 2 substitutes for the nitrogen of piperazine. Also shown is the pathway where an alkylene component (e.g., CH 2 ) is adjacent the piperazine or the N of CHNH of piperidine.
  • an alkylene component e.g., CH 2
  • Compound 5 is then reacted with diphenylamino acetic acid under conditions whereby an amide is formed with the unsubstituted piperazine ring nitrogen or the 4-amino group of piperidine.
  • the compound of formula (5) is reacted with an ⁇ -brominated form of the amide 7 to obtain the desired compound as shown. If Z is CHNR 2 , the 4-amino group substitutes for the nitrogen of the piperazine in this reaction.
  • the compounds of the invention can be synthesized individually using methods known in the art per se, or as members of a combinatorial library. [0053] Synthesis of combinatorial libraries is now commonplace in the art. Suitable descriptions of such syntheses are found, for example, in Wentworth, Jr., P., et ⁇ l, Current Opinion in Biol (1993) 9:109-115; Salemme, F. R., et ⁇ l, Structure (1997) 5:319-324.
  • the libraries contain compounds with various substituents and various degrees of unsaturation, as well as different chain lengths.
  • the libraries which contain, as few as 10, but typically several hundred members to several thousand members, may then be screened for compounds which are particularly effective against a specific subtype of calcium channel, i.e., the N-type channel.
  • the libraries may be screened for compounds which block additional channels or receptors such as sodium channels, potassium channels and the like.
  • Methods of performing these screening functions are well known in the art. These methods can also be used for individually ascertaining the ability of a compound to agonize or antagonize the channel.
  • the channel to be targeted is expressed at the surface of a recombinant host cell such as human embryonic kidney cells.
  • the ability of the members of the library to bind the channel to be tested is measured, for example, by the ability of the compound in the library to displace a labeled binding ligand such as the ligand normally associated with the channel or an antibody to the channel. More typically, ability to antagonize the channel is measured in the presence of calcium, barium or other permeant divalent cation and the ability of the compound to interfere with the signal generated is measured using standard techniques.
  • one method involves the binding of radiolabeled agents that interact with the calcium channel and subsequent analysis of equilibrium binding measurements including, but not limited to, on rates, off rates, K d values and competitive binding by other molecules.
  • Another method involves the screening for the effects of compounds by electrophysiological assay whereby individual cells are impaled with a microelectrode and currents through the calcium channel are recorded before and after application of the compound of interest.
  • Another method high-throughput spectrophotometric assay, utilizes loading of the cell lines with a fluorescent dye sensitive to intracellular calcium concentration and subsequent examination of the effects of compounds on the ability of depolarization by potassium chloride or other means to alter intracellular calcium levels.
  • a more definitive assay can be used to distinguish inhibitors of calcium flow which operate as open channel blockers, as opposed to those that operate by promoting inactivation of the channel or as resting channel blockers.
  • open-channel blockers are assessed by measuring the level of peak current when depolarization is imposed on a background resting potential of about - 100 mV in the presence and absence of the candidate compound. Successful open-channel blockers will reduce the peak current observed and may accelerate the decay of this cuirent.
  • Compounds that are inactivated channel blockers are generally determined by their ability to shift the voltage dependence of inactivation towards more negative potentials. This is also reflected in their ability to reduce peak currents at more depolarized holding potentials (e.g., -70 mV) and at higher frequencies of stimulation, e.g., 0.2 Hz vs. 0.03 Hz.
  • resting channel blockers would diminish the peak current amplitude during the very first depolarization after drug application without additional inhibition during the depolarization.
  • the compounds of the invention can be formulated as pharmaceutical or veterinary compositions.
  • the mode of administration, and the type of treatment desired e.g., prevention, prophylaxis, therapy; the compounds are formulated in ways consonant with these parameters.
  • a summary of such techniques is found in Remington's Pharmaceutical Sciences, latest edition, Mack Publishing Co., Easton, PA, incorporated herein by reference.
  • the compounds of formula (1) may be used alone, as mixtures of two or more compounds of formula (1) or in combination with other pharmaceuticals.
  • the compounds will be formulated into suitable compositions to permit facile delivery.
  • Fonnulations may be prepared in a manner suitable for systemic administration or topical or local administration.
  • Systemic formulations include those designed for injection (e.g., intramuscular, intravenous or subcutaneous injection) or may be prepared for transdermal, transmucosal, or oral administration.
  • the formulation will generally include a diluent as well as, in some cases, adjuvants, buffers, preservatives and the like.
  • the compounds can be administered also in liposomal compositions or as microemulsions.
  • formulations can be prepared in conventional forms as liquid solutions or suspensions or as solid forms suitable for solution or suspension in liquid prior to injection or as emulsions.
  • Suitable excipients include, for example, water, saline, dextrose, glycerol and the like. Such compositions may also contain amounts of nontoxic auxiliary substances such as wetting or emulsifying agents, pH buffering agents and the like, such as, for example, sodium acetate, sorbitan monolaurate, and so forth.
  • auxiliary substances such as wetting or emulsifying agents, pH buffering agents and the like, such as, for example, sodium acetate, sorbitan monolaurate, and so forth.
  • Various sustained release systems for drugs have also been devised. See, for example, U.S. patent No. 5,624,677.
  • Systemic administration may also include relatively noninvasive methods such as the use of suppositories, transdermal patches, transmucosal delivery and intranasal administration. Oral administration is also suitable for compounds of the invention.
  • Suitable forms include syrups, capsules, tablets, as is understood in the art.
  • the dosage of the compounds of the invention is typically 0.1-15 mg/kg, preferably 0.1-1 mg/kg. However, dosage levels are highly dependent on the nature of the condition, drug efficacy, the condition of the patient, the judgment of the practitioner, and the frequency and mode of administration.
  • N-type calcium channel blocking activity was assayed in human embryonic kidney cells, HEK 293, stably ttansfected with the rat brain N-type calcium channel subunits ( ⁇ -iB +ot 2 ⁇ + ⁇ i b cDNA subunits).
  • N-type calcium channels ⁇ - ⁇ ote + ⁇ ib cDNA subunits
  • L-type channels ⁇ -ic + ⁇ 2 ⁇ + ⁇ ib cDNA subunits
  • P/Q-type channels ⁇ i A + ⁇ 2 ⁇ + ⁇ i b cDNA subunits
  • DMEM Dulbecco's modified eagle medium
  • fetal bovine serum 200 U/ml penicillin and 0.2 mg/ml streptomycin
  • 5% CO 2 fetal bovine serum
  • trypsin/1 M EDTA 0.25% trypsin/1 M EDTA
  • plated at 10% confluency on glass coverslips At 12 hours the medium was replaced and the cells transiently ttansfected using a standard calcium phosphate protocol and the appropriate calcium channel cDNA's.
  • Fresh DMEM was supplied and the cells transferred to 2_°C/5°A ⁇ > CO 2 . Cells were incubated for 1 to 2 days before cell recording.
  • Cmrents were typically elicited from a holding potential of -80 mV to +10 mV using Clampex software (Axon Instruments). Typically, currents were first elicited with low frequency stimulation (0.067 Hz) and allowed to stabilize prior to application of the compounds. The compounds were then applied during the low frequency pulse trains for t wo to three minutes to assess tonic block, and subsequently the pulse frequency was increased to 0.2 Hz to assess frequency dependent block. Data were analyzed using Clampfit (Axon Instruments) and SigmaPlot 4.0 (Jandel Scientific). [0077] Specific data obtained for N-type channels are shown in Table 1 below. See Example 5 for structures.
  • Standard patch-clamp techniques were employed to identify blockers of T-type currents. Briefly, previously described HEK cell lines stably expressing human CX IG T-type channels were used for all the recordings (passage #: 4-20, 37°C, 5% CO 2 ). To obtain T-type currents, plastic dishes containing semi-confluent cells were positioned on the stage of a ZEISS AXIOVERT SI 00 microscope after replacing the culture medium with external solution (see below). Whole-cell patches were obtained using pipettes (borosilicate glass with filament, O.D.: 1.5 mm, ID.: 0.86 mm, 10 cm length), fabricated on a SUTTER P-97 puller with resistance values of ⁇ 5 M ⁇ (see below for internal solution).
  • T-type currents were reliably obtained by using two voltage protocols: (1) “non-inactivating", and (2) “inactivation"
  • the holding potential is set at -110 mV and with a pre-pulse at -100 mV for 1 second prior to the test pulse at -40 mV for 50 ms.
  • the pre-pulse is at approximately -85 mV for 1 second, which inactivates about 15% of the T-type channels.
  • test pulse - 40 mV, 50 ms 0.067 Hz
  • Vholding -110 rnV non-inactivated pre-pulse: -100 mV, 1 second u
  • Test compounds were dissolved in external solution, 0.1-0.01 % DMSO. After ⁇ 10 min rest, they were applied by gi'avity close to the cell using a WPI microfil tubing. The "non-inactivated" pre-pulse was used to examine the resting block of a compound. The “inactivated” protocol was employed to study voltage-dependent block. However, the initial data shown below were mainly obtained using the non-inactivated protocol only. IC 5 o values are shown for various compounds of the invention in Table 4.
  • Example 8 Activity of Invention Compounds in Formalin-Induced Pain Model
  • the effects of intrathecally delivered compounds of the invention on the rat formalin model were measured.
  • the compounds were reconstituted to stock solutions of approximately 10 mg/ml in propylene glycol.
  • Eight Holtzman male rats of 275-375 g size were randomly selected per test article.
  • the following study groups were used, with test article, vehicle control (propylene glycol) and saline delivered intraperitoneally (IP):
  • Rats that exhibited motor deficiency (such as paw-dragging) or failure to exhibit subsequent tactile allodynia were excluded from further testing. Sham control rats underwent the same operation and handling as the experimental animals, but without SNL. [0087] The method of Hargreaves and colleagues (Hargreaves, et al, 1988) was employed to assess paw-withdrawal latency to a thennal nociceptive stimulus. Rats were allowed to acclimate within a plexiglas enclosure on a clear glass plate maintained at 30°C. A radiant heat source (i.e., high intensity projector lamp) was activated with a timer and focused onto the plantar surface of the affected paw of nerve-injured or carrageenan-injected rats.
  • a radiant heat source i.e., high intensity projector lamp
  • Paw- withdrawal latency was determined by a photocell that halted both lamp and timer when the paw was withdrawn. The latency to withdrawal of the paw from the radiant heat source was determined prior to careageenan or L5/L5 SNL, 3 hours after carrageenan or 7 days after L5/L6 SNL but before drug and after drug administration. A maximal cut-off of 40 seconds was employed to prevent tissue damage. Paw withdrawal latencies were thus dete ⁇ nined to the nearest 0.1 second. Reversal of thermal hyperalgesia was indicated by a return of the paw withdrawal latencies to the pre-treatment baseline latencies (i.e., 21 seconds).
  • Anti nociception was indicated by a significant (p ⁇ 0.05) increase in paw withdrawal latency above this baseline.
  • Data were converted to % anti hyperalgesia by the formula: (lOOqx (test latency - baseline latency )/(cut-off - baseline latency) where cut-off was 21 seconds for determining anti hyperalgesia.
  • Compound 7 was administered orally in propylene glycol solution at a dose of 30 mg/kg. The percent activity was calculated for thermal hyperalgesia.
  • Vanegas, H. & Schaible, H-G. Effects of antagonists to high-threshold calcium channels upon spinal mechanism of pain, hyperalgesia and allodynia. Pain 85: 9-18. Wang, Y-X., Pettus, M., Philips, C, Gao, D., Bowersox, S.S. & Luther, R.R. (1998) Antinociceptive properties of a selective neuronal N-type calcium channel blocker, ziconotide (SNX-111), in rat model of post-operative pain. Soc Neurosci Abstr 24: 1626. Wentworth, P. Jr., & Janda, K.D. (1998) Generating and analyzing combinatorial chemistry libraries .

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Anesthesiology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Pyridine Compounds (AREA)

Abstract

L'invention concerne des composés de N-diarylaminoalkyl-substitués pipérazine/4-aminopipéridine de formule (1) dans laquelle A et B désignent individuellement une fraction à 6 chaînons, aromatique ou non aromatique, carbocyclique ou hétérocyclique ou représentent un aminoalykle et un élément parmi A et B peut représenter H ou alkyle (1-8C) ou A et B forment ensemble une fraction éventuellement substituée, à 6 chaînons, aromatique ou non aromatique, carbocyclique ou hétérocyclique ; R1 représente H ou alkyle (1-8C) ; Z désigne N ou CHNR2, où R2 désigne H ou alkyle (1-8C) ; X représente un alkylène à chaîne droite (1-4C), éventuellement au moins un carbone adjacent à un azote se présentant sous la forme de C=O ; chaque R3 représente un substituant indépendant ; n = 0-2 ; Ar désigne un cycle à 6 chaînons aromatique ou hétéroaromatique ; chaque fraction cyclique comprise dans A ou B et chaque fraction Ar dans la formule (1) pouvant être substituée par un ou plusieurs substituants. Ces composés et sels ou conjugués de ceux-ci sont capables de bloquer des canaux calciques de types N et T et sont utiles dans le traitement d'états induits par l'activité des canaux ioniques calciques, tels que des douleurs chroniques.
PCT/CA2005/000544 2004-04-09 2005-04-08 Derives de diarylamine utilises comme bloquants des canaux calciques WO2005097779A1 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
CA002562371A CA2562371A1 (fr) 2004-04-09 2005-04-08 Derives de diarylamine utilises comme bloquants des canaux calciques
MXPA06011629A MXPA06011629A (es) 2004-04-09 2005-04-08 Derivados de diarilamina como bloqueadores del canal de calcio.
AU2005231872A AU2005231872A1 (en) 2004-04-09 2005-04-08 Diarylamine derivatives as calcium channel blockers
JP2007506628A JP2007532492A (ja) 2004-04-09 2005-04-08 カルシウムチャネルブロッカーとしてのジアリールアミン誘導体
BRPI0509715-0A BRPI0509715A (pt) 2004-04-09 2005-04-08 derivados de diarilamina como canais bloqueadores de cálcio
EP05734348A EP1745042A4 (fr) 2004-04-09 2005-04-08 Derives de diarylamine utilises comme bloquants des canaux calciques

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US10/821,584 2004-04-09
US10/821,584 US20040259866A1 (en) 1998-06-30 2004-04-09 Calcium channel blockers comprising two benzhydril moieties
US10/928,564 2004-08-27
US10/928,564 US20050227999A1 (en) 2004-04-09 2004-08-27 Diarylamine derivatives as calcium channel blockers

Publications (1)

Publication Number Publication Date
WO2005097779A1 true WO2005097779A1 (fr) 2005-10-20

Family

ID=35124993

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA2005/000544 WO2005097779A1 (fr) 2004-04-09 2005-04-08 Derives de diarylamine utilises comme bloquants des canaux calciques

Country Status (7)

Country Link
EP (1) EP1745042A4 (fr)
JP (1) JP2007532492A (fr)
KR (1) KR20070044803A (fr)
AU (1) AU2005231872A1 (fr)
BR (1) BRPI0509715A (fr)
CA (1) CA2562371A1 (fr)
WO (1) WO2005097779A1 (fr)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1798220A1 (fr) 2005-12-16 2007-06-20 Neuropharma S.A. Derivés de dibenzène comme inhibiteurs des canaux calciques
WO2007068754A1 (fr) * 2005-12-16 2007-06-21 Neuropharma, S.A. Dérivés de dibenzène en tant que bloqueurs des canaux calciques
WO2008087421A3 (fr) * 2007-01-17 2009-07-23 King S College London Contraceptif masculin
US8247442B2 (en) 2006-03-29 2012-08-21 Purdue Pharma L.P. Benzenesulfonamide compounds and their use
US8399486B2 (en) 2007-04-09 2013-03-19 Purdue Pharma L.P. Benzenesulfonyl compounds and the use thereof
US8765736B2 (en) 2007-09-28 2014-07-01 Purdue Pharma L.P. Benzenesulfonamide compounds and the use thereof
US8791264B2 (en) 2006-04-13 2014-07-29 Purdue Pharma L.P. Benzenesulfonamide compounds and their use as blockers of calcium channels
US8937181B2 (en) 2006-04-13 2015-01-20 Purdue Pharma L.P. Benzenesulfonamide compounds and the use thereof
US9000174B2 (en) 2004-10-14 2015-04-07 Purdue Pharma L.P. 4-phenylsulfonamidopiperidines as calcium channel blockers

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2861231C (fr) * 2012-01-25 2021-04-13 Spinifex Pharmaceuticals Pty Ltd Derives de substitution d'acide piperazine-1-acetique et 1-acylperhydro-1,4-diazepines et leur utilisation comme antagonistes du recepteur de type 2 d'angiotensine ii

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5391552A (en) * 1990-09-13 1995-02-21 Pola Chemical Industries, Inc. Diphenylpiperazine derivative and drug for circulatory organ containing the same
US5646149A (en) * 1993-12-08 1997-07-08 Alcon Laboratories, Inc. Compounds having both potent calcium antagonist and antioxidant activity and use thereof as cytoprotective agents
WO1997024328A1 (fr) * 1995-12-27 1997-07-10 Bayer Aktiengesellschaft 2-amino-heterocycles et leurs utilisations therapeutiques
WO1999006383A1 (fr) * 1997-08-01 1999-02-11 Recordati S.A., Chemical And Pharmaceutical Company Derives piperazines agissant sur les voies urinaires inferieures
WO2001045709A1 (fr) * 1999-12-20 2001-06-28 Neuromed Technologies, Inc. Inhibiteurs calciques a base de piperazine et de piperidine substituees
US6294533B1 (en) * 1998-06-30 2001-09-25 Neuormed Technologies, Inc. Calcium channel blockers
WO2003076421A1 (fr) * 2002-03-13 2003-09-18 Janssen Pharmaceutica N.V. Derives aminocarbonyl utilises en tant que nouveaux inhibiteurs d'histone deacetylase
US20040034035A1 (en) * 1998-06-30 2004-02-19 Neuromed Technologies, Inc. Calcium channel inhibitors comprising benzhydril spaced from piperazine
US20040147529A1 (en) * 1998-06-30 2004-07-29 Snutch Terrance P. Preferentially substituted calcium channel blockers

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4411904A (en) * 1981-05-29 1983-10-25 Warner-Lambert Company Diphenylpropanamines, compositions thereof and use thereof
ES2010104A6 (es) * 1989-01-26 1989-10-16 Gema Sa Procedimiento de preparacion de ureas asimetricas y utilizacion de las mismas.
EP0853615B1 (fr) * 1995-09-15 2003-12-10 Neurosearch A/S Composes de piperidine utilises en tant qu'agents bloquants de canaux a calcium

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5391552A (en) * 1990-09-13 1995-02-21 Pola Chemical Industries, Inc. Diphenylpiperazine derivative and drug for circulatory organ containing the same
US5646149A (en) * 1993-12-08 1997-07-08 Alcon Laboratories, Inc. Compounds having both potent calcium antagonist and antioxidant activity and use thereof as cytoprotective agents
WO1997024328A1 (fr) * 1995-12-27 1997-07-10 Bayer Aktiengesellschaft 2-amino-heterocycles et leurs utilisations therapeutiques
WO1999006383A1 (fr) * 1997-08-01 1999-02-11 Recordati S.A., Chemical And Pharmaceutical Company Derives piperazines agissant sur les voies urinaires inferieures
US6294533B1 (en) * 1998-06-30 2001-09-25 Neuormed Technologies, Inc. Calcium channel blockers
US20040034035A1 (en) * 1998-06-30 2004-02-19 Neuromed Technologies, Inc. Calcium channel inhibitors comprising benzhydril spaced from piperazine
US20040147529A1 (en) * 1998-06-30 2004-07-29 Snutch Terrance P. Preferentially substituted calcium channel blockers
WO2001045709A1 (fr) * 1999-12-20 2001-06-28 Neuromed Technologies, Inc. Inhibiteurs calciques a base de piperazine et de piperidine substituees
WO2003076421A1 (fr) * 2002-03-13 2003-09-18 Janssen Pharmaceutica N.V. Derives aminocarbonyl utilises en tant que nouveaux inhibiteurs d'histone deacetylase

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CAO J. ET AL.: "Dual probes for dopamine transporter and s1 receptors:novel piperazinylkylbis (4'fluorophenylamine analogues as potential cocaine-abuse therapeutic agents.", JOURNAL OF MEDICINAL CHEMISTRY, vol. 46, no. 13, pages 2589 - 2598, XP008114796 *
KORZYCKA L. ET AL.: "Synthesis of asymmetric1,4-disubstuted piperazines and their psychotropic and cardiovascular actions.", POLISH JOURNAL OF PHARMACOLOGY AND PHARMACY, vol. 38, no. 5-6, 1986, pages 545 - 553, XP008114965 *
See also references of EP1745042A4 *

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9000174B2 (en) 2004-10-14 2015-04-07 Purdue Pharma L.P. 4-phenylsulfonamidopiperidines as calcium channel blockers
EP1798220A1 (fr) 2005-12-16 2007-06-20 Neuropharma S.A. Derivés de dibenzène comme inhibiteurs des canaux calciques
WO2007068754A1 (fr) * 2005-12-16 2007-06-21 Neuropharma, S.A. Dérivés de dibenzène en tant que bloqueurs des canaux calciques
US8247442B2 (en) 2006-03-29 2012-08-21 Purdue Pharma L.P. Benzenesulfonamide compounds and their use
US8791264B2 (en) 2006-04-13 2014-07-29 Purdue Pharma L.P. Benzenesulfonamide compounds and their use as blockers of calcium channels
US8937181B2 (en) 2006-04-13 2015-01-20 Purdue Pharma L.P. Benzenesulfonamide compounds and the use thereof
WO2008087421A3 (fr) * 2007-01-17 2009-07-23 King S College London Contraceptif masculin
US8927579B2 (en) 2007-01-17 2015-01-06 Nnaemkea Ikechukwu Amobi Male contraceptive
US8399486B2 (en) 2007-04-09 2013-03-19 Purdue Pharma L.P. Benzenesulfonyl compounds and the use thereof
US8765736B2 (en) 2007-09-28 2014-07-01 Purdue Pharma L.P. Benzenesulfonamide compounds and the use thereof

Also Published As

Publication number Publication date
EP1745042A4 (fr) 2010-07-14
KR20070044803A (ko) 2007-04-30
AU2005231872A1 (en) 2005-10-20
EP1745042A1 (fr) 2007-01-24
CA2562371A1 (fr) 2005-10-20
JP2007532492A (ja) 2007-11-15
BRPI0509715A (pt) 2007-09-18

Similar Documents

Publication Publication Date Title
US7649092B2 (en) Urea derivatives as calcium channel blockers
WO2005021523A1 (fr) Composes substitues par piperazine utilises en tant que bloqueurs de canaux de calcium
US20090286806A1 (en) Isoxazole derivatives as calcium channel blockers
US7507760B2 (en) N-type calcium channel blockers
EP1976841A1 (fr) Derives d'amide heterocyclique en tant qu'inhibiteur calcique
US20050227999A1 (en) Diarylamine derivatives as calcium channel blockers
US7511077B2 (en) Diamine calcium channel blockers
EP1745042A1 (fr) Derives de diarylamine utilises comme bloquants des canaux calciques
KR20070019639A (ko) 칼슘 채널 차단제로서 사용되는 피페라진 치환된 화합물

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: PA/a/2006/011629

Country of ref document: MX

Ref document number: 2562371

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2007506628

Country of ref document: JP

WWW Wipo information: withdrawn in national office

Ref document number: DE

WWE Wipo information: entry into national phase

Ref document number: 3048/KOLNP/2006

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2005734348

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2005231872

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1020067023525

Country of ref document: KR

ENP Entry into the national phase

Ref document number: 2005231872

Country of ref document: AU

Date of ref document: 20050408

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005231872

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 200580017235.0

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2005734348

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0509715

Country of ref document: BR